yahoo_financeOriginal article
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Data ReadoutpositiveLunsumioPositive
AI Analysis
Summary
Roche's Lunsumio combination therapy met its primary endpoint in a Phase 2 study for second-line follicular lymphoma treatment. This positive data readout supports the therapeutic potential of the Lunsumio-based combination regimen.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Met primary goal in 2L follicular lymphoma study
Importance:7/10
Sentiment:
0.75
Lunsumiofollicular lymphomaphase 2positive datacombination therapy
Related Companies
Read the original article
Published by yahoo_finance on September 17, 2026 2:48 PM